Alkermes (ALKS) Raw Materials (2011 - 2026)
Alkermes' (ALKS) quarterly Raw Materials came in at $70.1 million in Q2 2026, up 2.46% year-over-year from $68.4 million in Q2 2025, and down 1.21% quarter-over-quarter from $71.0 million in Q1 2026.
Analysis
Alkermes (ALKS) Raw Materials (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Raw Materials for 16 consecutive years, with $70.1 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Raw Materials rose 2.46% year-over-year to $70.1 million in Q2 2026; TTM through Jun 2026 was $70.1 million, a 2.46% increase from a year earlier, with the FY2025 full-year figure at $68.4 million, down 5.2% from the prior year.
- Raw Materials was $70.1 million for Q2 2026 at Alkermes, down from $71.0 million in the prior quarter.
- Over five years, Raw Materials peaked at $78.3 million in Q3 2024 and troughed at $51.4 million in Q1 2022.
- A 5-year average of $66.5 million and a median of $68.4 million in 2025 frame the typical range for Raw Materials.
- Across the five-year window, Raw Materials surged 31.54% in 2024 and slipped 15.47% in 2025, its largest moves.
- Over 5 years, Raw Materials stood at $61.1 million in 2022, then grew by 16.95% to $71.4 million in 2023, then climbed by 1.01% to $72.1 million in 2024, then declined by 5.2% to $68.4 million in 2025, then rose by 2.52% to $70.1 million in 2026.
- The last three Raw Materials figures came in at $70.1 million (Q2 2026), $71.0 million (Q1 2026), and $68.4 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.24 Bn | 625.48 Bn | 17.26 Bn |
| 2 | AbbVie | 441.52 Bn | 434.96 Bn | 12.70 Bn |
| 3 | Merck | 365.75 Bn | 358.60 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.61 Bn | 258.92 Bn | 11.24 Bn |
| 5 | Pfizer | 159.09 Bn | 147.39 Bn | 10.94 Bn |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 8 | Incyte | 25.32 Bn | 20.79 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.43 Bn | 18.77 Bn | 683.80 Mn |
| 10 | Alkermes | 7.56 Bn | 6.90 Bn | 397.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 70.11 Mn |
| Mar 31, 2026 | 70.97 Mn |
| Dec 31, 2025 | 68.39 Mn |
| Sep 30, 2025 | 66.23 Mn |
| Jun 30, 2025 | 68.42 Mn |
| Mar 31, 2025 | 69.69 Mn |
| Dec 31, 2024 | 72.14 Mn |
| Sep 30, 2024 | 78.34 Mn |
| Jun 30, 2024 | 76.12 Mn |
| Mar 31, 2024 | 76.56 Mn |
| Dec 31, 2023 | 71.42 Mn |
| Sep 30, 2023 | 68.32 Mn |
| Jun 30, 2023 | 57.87 Mn |
| Mar 31, 2023 | 59.05 Mn |
| Dec 31, 2022 | 61.06 Mn |
| Sep 30, 2022 | 57.89 Mn |
| Jun 30, 2022 | 52.87 Mn |
| Mar 31, 2022 | 51.43 Mn |
| Dec 31, 2021 | 56.13 Mn |
| Sep 30, 2021 | 46.25 Mn |